| 2023 | Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study
| CANCER RESEARCH AND TREATMENT |
| 2021 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
| INTERNATIONAL JOURNAL OF CANCER |
| 2020 | Finding Cardiac Resynchronization Therapy Responders: Postprocedural QRS-T Morphologies Matter
| KOREAN CIRCULATION JOURNAL |
| 2024 | Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression | KIDNEY INTERNATIONAL |
| 2014 | First case of nontuberculous mycobacterial lung disease caused by Mycobacterium marseillense in a patient with systemic lupus erythematosus | DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE |
| 2009 | First clinical trial of the "MiRo" capsule endoscope by using a novel transmission technology: electric-field propagation. | GASTROINTESTINAL ENDOSCOPY |
| 2011 | First Isolation of Streptococcus gallolyticus subsp. pasteurianus from a Korean Patient with Severe Septic Shock.
| Korean Journal of Clinical Microbiology (대한임상미생물학회지) |
| 2018 | First Report of a Living Liver Graft in Combined Lung and Liver Transplantation | TRANSPLANT INTERNATIONAL |
| 2021 | First step in the mysterious box of distal access site | INTERNATIONAL JOURNAL OF CARDIOLOGY |
| 2014 | First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
| BRITISH JOURNAL OF CANCER |
| 2014 | First-degree atrioventricular block is associated with advanced atrioventricular block, atrial fibrillation, and left ventricular dysfunction in patients with hypertension | JOURNAL OF HYPERTENSION |
| 2024 | First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2022 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2022 | First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2020 | First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
| EUROPEAN JOURNAL OF CANCER |
| 2022 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea | ANTICANCER RESEARCH |
| 2014 | First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
| CLINICAL GENITOURINARY CANCER |
| 2023 | First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
| CANCER MEDICINE |
| 2022 | First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. | JOURNAL OF CLINICAL ONCOLOGY |
